IP Verse

Use Of Carbamate Compound For Preventing, Alleviating Or Treating Absence Seizure Or Epilepsy Showing Absence Seizure - EP3711758

The patent EP3711758 was granted to SK Biopharmaceuticals on Mar 27, 2024. The application was originally filed on Nov 13, 2018 under application number EP18878222A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3711758

SK BIOPHARMACEUTICALS
Application Number
EP18878222A
Filing Date
Nov 13, 2018
Status
Granted And Under Opposition
Feb 23, 2024
Grant Date
Mar 27, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DENNEMEYER & ASSOCIATESDec 20, 2024DENNEMEYER & ASSOCIATESADMISSIBLE
HAMM & WITTKOPPDec 13, 2024HAMM & WITTKOPPADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2006112685
DESCRIPTIONWO2010150946
DESCRIPTIONWO2011046380
INTERNATIONAL-SEARCH-REPORTKR20080005437
INTERNATIONAL-SEARCH-REPORTKR20100137389
INTERNATIONAL-SEARCH-REPORTKR20120087124
OPPOSITIONEP3459543
OPPOSITIONEP3556349
OPPOSITIONUS2003171270
OPPOSITIONUS2006025397
OPPOSITIONUS2017182061
OPPOSITIONWO2006112685
OPPOSITIONWO2010150946
OPPOSITIONWO2019045121
SEARCHWO2006112685

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- L�SCHER WOLFGANG, "Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies", EPILEPSY RESEARCH, ELSEVIER SCIENCE PUBLISHERS , AMSTERDAM, NL, (20160801), vol. 126, doi:10.1016/J.EPLEPSYRES.2016.05.016, ISSN 0920-1211, pages 157 - 184, XP029709265
OPPOSITION- "Epilepsies: diagnosis and management (CG137) Clinical guideline", NICE - National Institute for Health and Care Excellence, (20200211), ISBN 978-1-4731-1790-7, XP093280601-
OPPOSITION- Barker‐haliski Melissa, Harte‐hargrove Lauren C., Ravizza Teresa, Smolders Ilse, Xiao Bo, Brandt Claudia, Löscher Wolfgang, "A companion to the preclinical common data elements for pharmacologic studies in animal models of seizures and epilepsy. A Report of the TASK3 Pharmacology Working Group of the ILAE/AES Joint Translational Task Force", Epilepsia Open, (20181101), vol. 3, no. S1, doi:10.1002/epi4.12254, ISSN 2470-9239, pages 53 - 68, XP093085480
OPPOSITION- Bassel Abou-Khalil, "Other Pharmacological Therapies: Investigational Antiepileptic Drugs, Animal Models of Epilepsy, Hormonal Therapy, Immunotherapy", Bassel Abou-Khalil, Mohamad Z. Koubeissi, Nabil J. Azar, Epilepsy Board Review, New York, Springer, (20170628), pages 241 - 245, doi:10.1007/978-1-4939-6774-2_19, ISBN 978-1-4939-6772-8, XP093252936
OPPOSITION- T.J. Feuerstein, "Kapitel 11 - Antikonvulsiva, Konvulsiva - Pharmakotherapie der Epilepsien", T.J. Feuerstein, Klaus Aktories , Ulrich Förstermann , Franz Hofmann , Klaus Starke, Allgemeine und spezielle Pharmakologie und Toxikologie, Elsevier Urban & Fischer, (20130101), pages 269 - 279, doi:10.1016/C2012-0-06299-0, ISBN 978-3-437-42523-3, XP093252923
OPPOSITION- Ozlem Akman , Tamer Demiralp , Nurbay Ates , Filiz Yilmaz Onat, "Electroencephalographic differences between WAG/Rij and GAERS rat models of absence epilepsy", Epilepsy Research, NL , (20100501), vol. 89, no. 2-3, doi:10.1016/j.eplepsyres.2009.12.005, ISSN 0920-1211, pages 185 - 193, XP026996985
OPPOSITION- Bialer, Meir, "Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)", Epilepsy Research, (20130101), vol. 103, doi:10.1016/j.eplepsyres.2012.10.001, XP055691206
OPPOSITION- Meir Bialer, "Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)", Epilepsy Research, NL , (20150301), vol. 111, doi:10.1016/j.eplepsyres.2015.01.001, ISSN 0920-1211, pages 85 - 141, XP055611172
OPPOSITION- Löscher Wolfgang, "Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies", Epilepsy Research, Elsevier Science publishers, NL , (20160801), vol. 126, doi:10.1016/j.eplepsyres.2016.05.016, ISSN 0920-1211, pages 157 - 184, XP029709265
OPPOSITION- Kang Jing-Qiong, "Defects at the crossroads of GABAergic signaling in generalized genetic epilepsies", Epilepsy Research (Author manuscript), NL , (20171101), vol. 137, doi:10.1016/j.eplepsyres.2017.08.013, ISSN 0920-1211, pages 1 - 24, XP093252943
OPPOSITION- Löscher Wolfgang, "Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs", SEIZURE, BAILLIERE TINDALL, GB , (20110601), vol. 20, no. 5, doi:10.1016/j.seizure.2011.01.003, ISSN 1059-1311, pages 359 - 368, XP093280623
OPPOSITION- Golyala Ambica; Kwan Patrick, "Drug development for refractory epilepsy: The past 25 years and beyond", Seizure, GB , (20161206), vol. 44, doi:10.1016/j.seizure.2016.11.022, ISSN 1059-1311, pages 147 - 156, XP029901803
OPPOSITION- John Gilchrist , Stacey Dutton , Marcelo Diaz-Bustamante , Annie McPherson , Nicolas Olivares , Jeet Kalia , Andrew Escayg ,Frank Bosmans, "Na v 1.1 Modulation by a Novel Triazole Compound Attenuates Epileptic Seizures in Rodents", ACS chemical biology, (20140516), vol. 9, no. 5, doi:10.1021/cb500108p, ISSN 1554-8929, pages 1204 - 1212, XP055362820
OPPOSITION- Wolfgang Löscher, Henrik Klitgaard, Roy E. Twyman, Dieter Schmidt, "New avenues for anti-epileptic drug discovery and development", Nature Reviews Drug Discovery, GB , (20131001), vol. 12, no. 10, doi:10.1038/nrd4126, ISSN 1474-1776, pages 757 - 776, XP055253606
OPPOSITION- Knake S, Hamer H.M, Schomburg U, Oertel W.H, Rosenow F, "Tiagabine-induced absence status in idiopathic generalized epilepsy", SEIZURE, BAILLIERE TINDALL, GB , (19990801), vol. 8, no. 5, doi:10.1053/seiz.1999.0303, ISSN 1059-1311, pages 314 - 317, XP093280612
OPPOSITION- Glauser Tracy A, Cnaan Avital, Shinnar Shlomo, Hirtz Deborah G, Dlugos Dennis, Masur David, Clark Peggy O, Capparelli Edmund V, Adamson Peter C, , "Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy", The New England Journal of Medicine, (20100304), vol. 362, no. 9, doi:10.1056/nejmoa0902014, pages 790 - 799, XP093280577
OPPOSITION- Robert S. Fisher; J. Helen Cross; Carol D'Souza; Jacqueline A. French; Sheryl R. Haut; Norimichi Higurashi; Edouard Hirsch; Floor E. Jansen; Lieven Lagae; Solomon L. Moshé; Jukka Peltola; Eliane Roulet Perez; Ingrid E. Scheffer; Andreas Schulze‐Bonhage; Ernest Somerville; Michael Sperling; Elza Márcia Yacubian; Sameer M. Zuberi, "Instruction manual for the ILAE 2017 operational classification of seizure types", Epilepsia, New York , US , (20170308), vol. 58, no. 4, doi:10.1111/epi.13671, ISSN 0013-9580, pages 531 - 542, XP071213725
OPPOSITION- Carl E Stafstrom, " Persistent Sodium Current and Its Role in Epilepsy", Epilepsy Currents, (20070101), vol. 7, no. 1, doi:10.1111/j.1535-7511.2007.00156.x, pages 15 - 22, XP055337014
OPPOSITION- Kenou van Rijckevorsel, "Treatment of Lennox-Gastaut syndrome: overview and recent findings", Neuropsychiatric Disease and Treatment, (20081201), vol. 4, no. 6, doi:10.2147/ndt.s1668, pages 1001 - 1019, XP093252950
OPPOSITION- Shikha Kumari, Chandra Bhushan Mishra , Manisha Tiwari, "Polypharmacological Drugs in the Treatment of Epilepsy: The Comprehensive Review of Marketed and New Emerging Molecules", Current Pharmaceutical Design , (20160101), vol. 22, no. 21, doi:10.2174/1381612822666160226144200, ISSN 1381-6128, pages 3212 - 3225, XP093252928
OPPOSITION- Gaetano Zaccara, D. Schmidt, "Antiepileptic Drugs in Clinical Development: Differentiate or Die?", Current Pharmaceutical Design, NL , (20180209), vol. 23, no. 37, doi:10.2174/1381612823666170809100524, ISSN 1381-6128, pages 5593 - 5605, XP055507491
OPPOSITION- Eskioglou Elissavet, Perrenoud Matthieu P., Ryvlin Philippe, Novy Jan, "Novel Treatment and New Drugs in Epilepsy Treatment", Current Pharmaceutical Design, NL , (20180215), vol. 23, no. 42, doi:10.2174/1381612823666171024143541, ISSN 1381-6128, pages 6389 - 6398, XP093252924
SEARCH- MEIR BIALER ET AL, "Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)", EPILEPSY RESEARCH, NL, (20130101), vol. 103, no. 1, doi:10.1016/j.eplepsyres.2012.10.001, ISSN 0920-1211, pages 2 - 30, XP055691206 [X] 1-4,6-7,9-12,14-15 * page 5; table 1 * * page 14; table 2 * * pages 25, 26 * [I] 5,8,13,16
SEARCH[ ] - GOLYALA AMBICA ET AL, "Drug development for refractory epilepsy: The past 25 years and beyond", SEIZURE, BAILLIERE TINDALL, LONDON, GB, (20161206), vol. 44, doi:10.1016/J.SEIZURE.2016.11.022, ISSN 1059-1311, pages 147 - 156, XP029901803 [ ] * page 147, line last - page 148, line first *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents